New treatments for systemic lupus erythematosus
Official title: Novel Immunoregulatory Therapeutics for Systemic Lupus Erythematosus
Funded at Biotherapeutics, INC. · NIH-10654040 · Data updated 2026-11-12
This study is exploring new medications to help people with lupus, a condition that affects the immune system, by testing them in mice to see how well they work and if they are safe, with the hope of finding better treatments for patients like you.
Quick facts
| Grant type | Sbir 2 grant |
|---|---|
| Study type | NIH-funded research |
| Funding institution | Biotherapeutics, INC. NIH-funded |
| Lab location | 1 site (Blacksburg, United States) |
| Project start | January 1, 2021 |
| Project end | June 30, 2025 |
| Funding year | 2023 |
| Award (this year) | $563,659 |
| NIH project number | 5R44AI156952-03 |
| Project ID | NIH-10654040 on NIH RePORTER |
Who could benefit from this research
✓Could help
Ideal candidates for this research are individuals diagnosed with systemic lupus erythematosus who may not be responding well to current treatments.
✕Less likely to help
Patients with other autoimmune diseases or those not diagnosed with systemic lupus erythematosus may not benefit from this research.
What this research studies
This research focuses on developing novel immunoregulatory drugs aimed at treating systemic lupus erythematosus (SLE), an autoimmune disease affecting millions. The approach combines advanced computational modeling with experimental methods to evaluate the efficacy and safety of new therapeutic compounds. The research will involve testing these compounds in mouse models and assessing their effects on disease markers and kidney health. Patients may benefit from innovative treatments that could improve their condition and quality of life.
Why it matters
Potential benefit: If successful, this research could lead to more effective and targeted therapies for patients with systemic lupus erythematosus.
How similar studies have gone: Previous research has shown promising results with similar immunoregulatory approaches in treating autoimmune conditions, indicating potential for success in this area.
Where this research is happening
-
Biotherapeutics, INC.
Blacksburg, United States Active
Researchers
- Principal investigator: Leber, Andrew — Biotherapeutics, INC.
- Study coordinator: Leber, Andrew
Related research
Other NIH-funded projects on the same topics.
-
Immunostimulatory short non-coding RNAs and lupus
A study in people with lupus looks at tiny RNA pieces that may spark inflammation, to understand if they drive disease activity.
-
Antiviral factors that limit HIV in people with SLE
Researchers at Howard University are studying how immune factors in people with lupus may help limit HIV infection.
-
Mechanistic clues about lupus from immune disorders
This grant looks at why certain immune disorders in people with genetic immune problems lead to lupus-like symptoms, by studying patients and mouse models.
-
Subjective thinking challenges in adults with lupus as they age
This grant aims to understand how lupus-related cognitive problems affect adults, especially older adults, and tests a real-time method to track daily fluctuations in those symptoms.
-
Mitochondrial targets of antibodies in lupus (SLE)
A Johns Hopkins-led study will identify which mitochondrial membrane proteins are targeted by autoantibodies in lupus patients to understand how these immune attacks fuel the disease.
-
Influenza, Hydroxychloroquine, and the Windows of Self-Peptide Presentation in Lupus
A doctor-researcher is studying how flu infection and the lupus medication hydroxychloroquine change the way the immune system shows self-parts to trigger or prevent lupus flares in kids.
About this research
- This is an active NIH-funded research project — typically early-stage science, not a clinical trial accepting patient enrollment.
- Some NIH-funded labs run parallel clinical studies or seek volunteers for related work. To check, contact the principal investigator or institution listed above.
- For full project details, budget, and progress reports, visit the official NIH RePORTER page.